1 |
Jenkins T, Gouge J. Nrf2 in Cancer, Detoxifying Enzymes and Cell Death Programs. Antioxidants (Basel) 2021;10:1030. [PMID: 34202320 DOI: 10.3390/antiox10071030] [Reference Citation Analysis]
|
2 |
Zhu W, Ge M, Li X, Wang J, Wang P, Tai T, Wang Y, Sun J, Shi G. Hyperoside Attenuates Zearalenone-induced spleen injury by suppressing oxidative stress and inhibiting apoptosis in mice. Int Immunopharmacol 2022;102:108408. [PMID: 34920313 DOI: 10.1016/j.intimp.2021.108408] [Reference Citation Analysis]
|
3 |
Xu S, Chen S, Xia W, Sui H, Fu X. Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity. Molecules 2022;27:3009. [DOI: 10.3390/molecules27093009] [Reference Citation Analysis]
|
4 |
Arunachalam A, Lakshmanan DK, Ravichandran G, Paul S, Manickam S, Kumar PV, Thilagar S. Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer. Med Oncol 2021;38:122. [PMID: 34482423 DOI: 10.1007/s12032-021-01573-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Mafra D, Alvarenga L, Cardozo LF, Stockler-pinto MB, Nakao LS, Stenvinkel P, Shiels PG. Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases. Biochimica et Biophysica Acta (BBA) - General Subjects 2022. [DOI: 10.1016/j.bbagen.2022.130129] [Reference Citation Analysis]
|